Dr Spiess talks about taking part in an international consortium that seeks to establish a standard treatment for penile cancer, the ways shame interferes with diagnosis and treatment, and the complicated issues of gender and sexuality involved with this disease.

Dr Tarantino discusses practice-changing findings in breast cancer and emphasizes the ways in which positive study data can improve the breast cancer treatment paradigm going forward.

Dr Duma discusses improving diversity in trials and in oncology providers, how the oncology field fails women in general and women of color in particular, and the stress lung cancer puts on a woman’s home life.

Dr Duma discusses the leading causes of lung cancer in women, the ongoing failure to screen a sufficient number of women for lung cancer, and how gender bias interferes with treatment.

Drs Karp, Raza, and Le Beau discuss challenges they faced in their early careers as women in leukemia, the ways they overcame those obstacles, and the unique pitfalls and successes they’ve experienced as female physicians.

Dr Khan expands on key data found on racial disparities in surgical outcomes for gastrointestinal tract cancer and addresses the need to reduce the gap in these outcomes.

Dr Wise highlights how intensified treatment with doublet or triplet therapy can lead to better long-term outcomes in prostate cancer, potential treatment sequencing options, and the importance of communication between patients and physicians.

Dr Lee highlights the latest treatment developments in non–clear cell renal cell carcinoma, emphasizes the need for more precise classification of the histologic subsets of this disease, and discusses the investigation of cabozantinib plus nivolumab across stratified cohorts of non–clear cell renal cell carcinoma.

Dr Ueno discusses the challenges of diagnosing inflammatory breast cancer, the unmet need for new agents to treat patients with the disease, and the current ongoing research he’s eager to see reported.

Dr Hua talks about the unmet need in neuroendocrine tumors (NETs), explains the difficulty of detecting NETs, and highlights his study findings evaluating anti-CDH17 CAR T cells in this disease.